TY - JOUR
T1 - Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma
T2 - A Literature Review
AU - Nelson, Blessie Elizabeth
AU - Hong, Angelina
AU - Jana, Bagi
N1 - Publisher Copyright:
© Copyright © 2021 Nelson, Hong and Jana.
PY - 2021/8/5
Y1 - 2021/8/5
N2 - Urothelial carcinoma therapy is a rapidly evolving and expanding field. Traditional cytotoxic chemotherapy regimens have not produced optimal long-term outcomes, and many urothelial cancer patients have comorbidities that disqualify them as chemotherapy candidates. In recent years, a plethora of novel therapeutic agents that target diverse molecular pathways has emerged as alternative treatment modalities for not only metastatic urothelial carcinoma, but also for muscle-invasive bladder cancer and non-muscle invasive bladder cancer in adjuvant and definitive settings. This review paper aims to discuss the various categories of therapeutic agents for these different types of urothelial cancer, discussing immunotherapy, antibody-drug conjugates, kinase inhibitors, CAR-T cell therapy, peptide vaccination, and other drugs targeting pathways such as angiogenesis, DNA synthesis, mTOR/PI3K/AKT, and EGFR/HER-2.
AB - Urothelial carcinoma therapy is a rapidly evolving and expanding field. Traditional cytotoxic chemotherapy regimens have not produced optimal long-term outcomes, and many urothelial cancer patients have comorbidities that disqualify them as chemotherapy candidates. In recent years, a plethora of novel therapeutic agents that target diverse molecular pathways has emerged as alternative treatment modalities for not only metastatic urothelial carcinoma, but also for muscle-invasive bladder cancer and non-muscle invasive bladder cancer in adjuvant and definitive settings. This review paper aims to discuss the various categories of therapeutic agents for these different types of urothelial cancer, discussing immunotherapy, antibody-drug conjugates, kinase inhibitors, CAR-T cell therapy, peptide vaccination, and other drugs targeting pathways such as angiogenesis, DNA synthesis, mTOR/PI3K/AKT, and EGFR/HER-2.
KW - bladder cancer
KW - clinical trials
KW - FDA approvals
KW - molecular targets
KW - targeted therapy
KW - urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85113173934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113173934&partnerID=8YFLogxK
U2 - 10.3389/fonc.2021.705294
DO - 10.3389/fonc.2021.705294
M3 - Review article
C2 - 34422659
AN - SCOPUS:85113173934
SN - 2234-943X
VL - 11
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 705294
ER -